TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Alto Neuroscience Stock

Alto Neuroscience Stock

altoneuroscience.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $151.37MM

Alto Neurosciences is a biopharma company that uses biomarkers of the brain to understand prospective drug therapies for psychiatric care of patients. Alto Neurosciences specializes in precision medicine, and has established a pipeline of treatments for various mental health conditions such as post-traumatic stress disorders (PTSD) and depression.

Learn more about Alto Neuroscience IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Alto Neuroscience, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Alto Neuroscience’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Alto Neuroscience.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Alto Neuroscience investors also invested in these private companies

Valor Equity Partners
Gaingels
Vine Ventures
Point72 Ventures
What If Ventures
Novartis
NJF Capital
National Institutes of Health
Windham Venture Partners
Sobrato Capital
Korify Capitals
Alpha Wave Global
re.Mind Capital
Able Partners
Bioverge Ventures
K2 HealthVentures
InVivium Capital
Lightswitch Capital
Catena Capital
Presight Capital

Team

Management Team

Amit Etkin Ph.D
Co-Founder & Chief Executive Officer
Nick Smith
Chief Financial Officer & Chief Business Officer
Dan Segal
Co-Founder, Chief Strategy Officer & Chief Operating Officer
Mikael Eliasson MD
Chief Operating Officer
Erin McQuade JD
Chief Administrative Officer & General Counsel
Jessica Powell
Chief Development Officer
Wei Wu Ph.D
Co-Founder & Chief Data Science Officer
Adam Savitz Ph.D
Chief Medical Officer

Board Members

Aaron Weaver
Apeiron Investment Group
Chris Dimitropoulos
Alpha Wave Global
Christopher Cox JD
Lightswitch Capital
Michael Liang Ph.D
InVivium Capital

Other companies like Alto Neuroscience in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Prime Medicine

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.23B

ADARx Pharmaceuticals

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

News Highlights

Business Wire 11/21/2023
Alto Neuroscience Closes $45 Million in Oversubscribed Series C Financing
Alto Neuroscience, Inc. today announced an oversubscribed $45 million Series C financing. The round was led by InVivium Capital, with participation from additional new investors Franklin Templeton, Point72, Eli Lilly and Company, and Alexandria Venture Investments. Existing investors Alpha Wave Ventures, Lightswitch Capital, partners of Alkeon Capital, WhatIf Ventures, and Windham Venture Partners also participated in the financing.
Businesswire 10/31/2022
Alto Neuroscience Announces $35 Million Series B Financing
Alto Neuroscience today announced the closing of a $35 million Series B financing led by Lightswitch Capital and partners of Alkeon Capital, with participation from other new investors including Sobrato Capital, Novartis Pharma AG, Valor Equity Partners, Korify Capital, Vine Ventures, and Gaingels.

Trending Companies

Frequently Asked Questions

Updated on: Apr 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.